Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy

BACKGROUND: We conducted a phase I/II clinical trial to evaluate the efficacy of eribulin and olaparib in a tablet form (EO study) for triple-negative breast cancer (TNBC) patients. We hypothesized that somatic BRCA mutations and homologous recombination repair (HRR)-related gene alterations might a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimomura, Akihiko, Yonemori, Kan, Yoshida, Masayuki, Yoshida, Teruhiko, Yasojima, Hiroyuki, Masuda, Norikazu, Aogi, Kenjiro, Takahashi, Masato, Naito, Yoichi, Shimizu, Satoru, Nakamura, Rikiya, Hamada, Akinobu, Michimae, Hirofumi, Hashimoto, Jun, Yamamoto, Harukaze, Kawachi, Asuka, Shimizu, Chikako, Fujiwara, Yasuhiro, Tamura, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698310/
https://www.ncbi.nlm.nih.gov/pubmed/31382135
http://dx.doi.org/10.1016/j.tranon.2019.07.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698310/
https://www.ncbi.nlm.nih.gov/pubmed/31382135
http://dx.doi.org/10.1016/j.tranon.2019.07.013

Ejemplares similares